Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity
MA Knowles, CD Hurst - Nature reviews cancer, 2015 - nature.com
Urothelial carcinoma of the bladder comprises two long-recognized disease entities with
distinct molecular features and clinical outcome. Low-grade non-muscle-invasive tumours …
distinct molecular features and clinical outcome. Low-grade non-muscle-invasive tumours …
Targeting FGFR signaling in cancer
The fibroblast growth factor signaling pathway (FGFR signaling) is an evolutionary
conserved signaling cascade that regulates several basic biologic processes, including …
conserved signaling cascade that regulates several basic biologic processes, including …
Cellular signaling by fibroblast growth factor receptors
The 22 members of the fibroblast growth factor (FGF) family of growth factors mediate their
cellular responses by binding to and activating the different isoforms encoded by the four …
cellular responses by binding to and activating the different isoforms encoded by the four …
[HTML][HTML] Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
The fibroblast growth factor receptor (FGFR) cascade plays crucial roles in tumor cell
proliferation, angiogenesis, migration and survival. Accumulating evidence suggests that in …
proliferation, angiogenesis, migration and survival. Accumulating evidence suggests that in …
FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer
DC Tomlinson, O Baldo, P Harnden… - The Journal of …, 2007 - Wiley Online Library
FGFR3 is frequently activated by mutation in urothelial carcinoma (UC) and represents a
potential target for therapy. In multiple myeloma, both over‐expression and mutation of …
potential target for therapy. In multiple myeloma, both over‐expression and mutation of …
Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?
MA Knowles - Carcinogenesis, 2006 - academic.oup.com
Cancer of the bladder shows divergent clinical behaviour following diagnosis and it has
been proposed that two major groups of tumours exist that develop via different molecular …
been proposed that two major groups of tumours exist that develop via different molecular …
FGFR3 and P53 Characterize Alternative Genetic Pathways in the Pathogenesis of Urothelial Cell Carcinoma
Fibroblast growth factor receptor 3 (FGFR3) and P53 mutations are frequently observed in
bladder cancer. We here describe the distribution of FGFR3 mutations and P53 …
bladder cancer. We here describe the distribution of FGFR3 mutations and P53 …
De-regulated FGF receptors as therapeutic targets in cancer
V Knights, SJ Cook - Pharmacology & therapeutics, 2010 - Elsevier
Fibroblast growth factors (FGFs) acting through their cognate receptors (FGFRs) play vital
roles in development and de-regulation of FGF/FGFR signalling is associated with many …
roles in development and de-regulation of FGF/FGFR signalling is associated with many …
Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium
Despite the fact that the current histopathologic classification for bladder cancer has led to
improved concepts for the clinical management of the disease, key questions with regard to …
improved concepts for the clinical management of the disease, key questions with regard to …
Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of …
Fibroblast growth factor receptors (FGFRs) can act as driving oncoproteins in certain
cancers, making them attractive drug targets. Here we have characterized tumour cell …
cancers, making them attractive drug targets. Here we have characterized tumour cell …